Certara, Inc. $CERT Shares Sold by 2Xideas AG

2Xideas AG trimmed its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 41.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 184,198 shares of the company’s stock after selling 130,568 shares during the period. 2Xideas AG owned approximately 0.12% of Certara worth $2,251,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CERT. iSAM Funds UK Ltd grew its holdings in Certara by 68.6% during the third quarter. iSAM Funds UK Ltd now owns 34,141 shares of the company’s stock worth $417,000 after acquiring an additional 13,891 shares during the period. Nicolet Advisory Services LLC lifted its stake in Certara by 7.4% during the third quarter. Nicolet Advisory Services LLC now owns 30,608 shares of the company’s stock valued at $396,000 after purchasing an additional 2,100 shares during the last quarter. Alpha Wave Global LP acquired a new stake in Certara during the third quarter valued at approximately $6,168,000. Brown Brothers Harriman & Co. boosted its holdings in Certara by 34.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,764,034 shares of the company’s stock worth $45,996,000 after buying an additional 972,669 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Certara by 10.2% in the third quarter. Invesco Ltd. now owns 577,501 shares of the company’s stock valued at $7,057,000 after buying an additional 53,536 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors.

Certara Stock Up 1.4%

CERT opened at $6.65 on Friday. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -665.00 and a beta of 1.50. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.05 and a current ratio of 2.05. The firm’s 50-day simple moving average is $7.98 and its 200-day simple moving average is $9.62. Certara, Inc. has a twelve month low of $6.04 and a twelve month high of $15.38.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). The firm had revenue of $103.65 million for the quarter, compared to the consensus estimate of $103.23 million. Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. The company’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.15 earnings per share. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. Equities research analysts anticipate that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on CERT shares. Morgan Stanley dropped their price target on Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 18th. Rothschild & Co Redburn set a $10.00 target price on shares of Certara in a report on Friday, November 21st. Barclays restated an “equal weight” rating and set a $8.00 price target on shares of Certara in a report on Friday, March 6th. TD Cowen reaffirmed a “buy” rating on shares of Certara in a research note on Thursday, February 26th. Finally, Wall Street Zen downgraded shares of Certara from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $11.10.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.